Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion

Bibliography

• Alexander HR Jr, Butler CC. Development of isolated hepatic perfusion via the operative and percutaneous techniques for patients with isolated and unresectable liver metastases. Cancer J 2010;16:132-41
   PubMed Web of Science ®Google Scholar
• Gimbel MI, Delman KA, Zager JS. Therapy for unresectable recurrent and in-transit extremity melanoma. Cancer Contr 2008;15:225-32
   PubMedGoogle Scholar
• Padsis J, Turley R, Tyler D. Pharmacotherapy of regional melanoma therapy. Expert Opin Pharmacother 2010;11:79-93
   PubMed Web of Science ®Google Scholar
• Lawrence W Jr. Regional cancer chemotherapy: an evaluation. Prog Clin Cancer 1965;10:341-93
   PubMedGoogle Scholar
• Lawrence W Jr, Clarkson B, Kim M, et al. Regional perfusion of pelvis and abdomen by an indirect technique. Acta Unio Int Contra Cancrum 1964;20:469-73
   PubMedGoogle Scholar
• Lawrence W Jr, Kuehn P, Masle ET, Miller DG. An abdominal tourniquet for regional chemotherapy. J Surg Res 1961;1:142-51
   PubMedGoogle Scholar
• Lawrence W Jr, Kuehn P, Mori S, et al. Regional perfusion of the pelvis: consideration of the "leakage" problem. Surgery 1961;50:248-59
   PubMed Web of Science ®Google Scholar
• Han D, Beasley GM, Tyler DS, Zager JS. Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion. Expert Opin Drug Metab Toxicol 2011;7:1383-94
   PubMed Web of Science ®Google Scholar
• Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003;44:4651-9
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206
   PubMed Web of Science ®Google Scholar
• Zogakis TG, Bartlett DL, Libutti SK, et al. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma. Ann Surg Oncol 2001;8:771-8
   PubMed Web of Science ®Google Scholar
• Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 2008;15:2195-205
   PubMed Web of Science ®Google Scholar
• Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 2008;15:3003-13
   PubMed Web of Science ®Google Scholar
• Raymond AK, Beasley GM, Broadwater G, et al. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg 2011;213:306-16
   PubMed Web of Science ®Google Scholar
• Chai CY, Deneve JL, Beasley GM, et al. A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. Ann Surg Oncol 2012;19:1637-43
   PubMed Web of Science ®Google Scholar
• Vohra NA, Turaga KK, Gonzalez RJ, et al. The use of isolated limb infusion in limb threatening extremity sarcomas. Int J Hyperthermia 2013;29:1-7
   PubMed Web of Science ®Google Scholar
• Wong J, Chen YA, Fisher KJ, Zager JS. Isolated limb infusion in a series of over 100 infusions: a single-center experience. Ann Surg Oncol 2013;20:1121-7
   PubMed Web of Science ®Google Scholar
• Bonenkamp JJ, Thompson JF, de Wilt JH, et al. Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. Eur J Surg Oncol 2004;30:1107-12
   PubMed Web of Science ®Google Scholar
• Ueno T, Ko SH, Grubbs E, et al. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am J Surg 2004;188:532-7
   PubMed Web of Science ®Google Scholar
• Quirt I, Verma S, Petrella T, et al. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist 2007;12:1114-23
   PubMed Web of Science ®Google Scholar
• Beasley GS, Speicher PJ, Jiang B, et al. A multi-center phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion. Society of Surgical Oncology Cancer Symposium; Phoenix, AZ; 2014; Duke University
   Google Scholar
• Turaga KK, Beasley GM, Kane JM III, et al. Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms. Arch Surg 2011;146:870-5
   PubMed Web of Science ®Google Scholar
• Grubbs EG, Rich TA, Li G, et al. Recent advances in thyroid cancer. In brief. Curr Probl Surg 2008;45:149-51
   PubMedGoogle Scholar
• Wu PC, McCart A, Hewitt SM, et al. Isolated organ perfusion does not result in systemic microembolization of tumor cells. Ann Surg Oncol 1999;6:658-63
   PubMed Web of Science ®Google Scholar
• Santillan AA, Delman KA, Beasley GM, et al. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol 2009;16:2570-8
   PubMed Web of Science ®Google Scholar
• Thompson JF. Local and regional therapies for melanoma: many arrows in the quiver. J Surg Oncol 2014;109:295
   PubMed Web of Science ®Google Scholar
• Roberts MS, Wu ZY, Siebert GA, et al. Saturable dose-response relationships for melphalan in melanoma treatment by isolated limb infusion in the nude rat. Melanoma Res 2001;11:611-18
   PubMed Web of Science ®Google Scholar
• Cheng TY, Grubbs E, Abdul-Wahab O, et al. Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. Am J Surg 2003;186:460-7
   PubMed Web of Science ®Google Scholar
• McMahon N, Cheng TY, Beasley GM, et al. Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol 2009;16:953-61
   PubMed Web of Science ®Google Scholar
• Harada N, Nagasaki A, Hata H, et al. Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake. Acta Haematol 2000;103:144-51
   PubMed Web of Science ®Google Scholar
• Clark J, Grabs AJ, Parsons PG, et al. Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma. Melanoma Res 1994;4:365-70
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab OI, Grubbs E, Viglianti BL, et al. The role of hyperthermia in regional alkylating agent chemotherapy. Clin Cancer Res 2004;10:5919-29
   PubMed Web of Science ®Google Scholar
• Muilenburg DJ, Thompson ZJ, Lee J, Zager JS. Disease burden predicts response to melphalan-based isolated limb infusion in melanoma. H. Lee Moffitt Cancer Center and Research Institute, Presented at the Society of Surgical Oncology Annual Meeting, Phoenix, AZ, 2014
   Google Scholar
• Augustine CK, Yoshimoto Y, Gupta M, et al. Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res 2008;68:3777-84
   PubMed Web of Science ®Google Scholar
• Toshimitsu H, Yoshimoto Y, Augustine CK, et al. Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma. Ann Surg Oncol 2010;17:2247-54
   PubMed Web of Science ®Google Scholar
• Dickson PV, Hamner JB, Sims TL, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007;13:3942-50
   PubMed Web of Science ®Google Scholar
• Turley RS, Fontanella AN, Padussis JC, et al. Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma. Clin Cancer Res 2012;18:3328-39
   PubMed Web of Science ®Google Scholar
• Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12:426-37
   PubMed Web of Science ®Google Scholar
• Beasley GM, Sharma K, Wong J, et al. A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion. Cancer 2012;118:6136-43
   PubMed Web of Science ®Google Scholar
• Jilaveanu L, Zito C, Lee SJ, et al. Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin Cancer Res 2009;15:1076-85
   PubMed Web of Science ®Google Scholar
• Kim MW, Blum C, Alosi AB, et al. Combined with Isolated Limb Perfusion (ILP) for extremity melanoma. Roswell Park Cancer Institute; 2014
   Google Scholar
• Sato T. Locoregional management of hepatic metastasis from primary uveal melanoma. Semin Oncol 2010;37:127-38
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Eggermont AM, O’Day S, Zager JS. Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer 2014;120:781-9
   PubMed Web of Science ®Google Scholar
• Beheshti MV, Denny DF Jr, Glickman MG, et al. Percutaneous isolated liver perfusion for treatment of hepatic malignancy: preliminary report. J Vasc Interv Radiol 1992;3:453-8
   PubMedGoogle Scholar
• Feldman ED, Pingpank JF, Alexander HR Jr. Regional treatment options for patients with uveal melanoma metastatic to the liver. Ann Surg Oncol 2004;11:290-7
   PubMed Web of Science ®Google Scholar
• Ausman RK. Development of a technic for isolated perfusion of the liver. N Y State J Med 1961;61:3993-7
   PubMedGoogle Scholar
• Pingpank JF, Hughes MS, Faries MB, et al. A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic uveal or cutaneous melanoma. J Clin Oncol 2010;28(18S Suppl):abstract LBA8512
   Google Scholar
• Pingpank JF, Libutti SK, Chang R, et al. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 2005;23:3465-74
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Zager JS. Isolated hepatic perfusion for metastatic melanoma. J Surg Oncol 2014;109:383-8
   PubMed Web of Science ®Google Scholar
• Forster MR, Rashid OM, Perez MC, et al. Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience. J Surg Oncol 2014;109:434-9
   PubMed Web of Science ®Google Scholar
• Fitzpatrick M, Richard Alexander H, Deshpande SP, et al. Use of partial venovenous cardiopulmonary bypass in percutaneous hepatic perfusion for patients with diffuse, isolated liver metastases: a case series. J Cardiothorac Vasc Anesth 2014;28(3):647-51
   PubMed Web of Science ®Google Scholar
• Ravikumar TS, Pizzorno G, Bodden W, et al. Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. J Clin Oncol 1994;12:2723-36
   PubMed Web of Science ®Google Scholar
• Alexander HR. Percutaneous hepatic perfusion (PHP or ChemoSat) with melphalan versus best alternative care (BAC) in patients (pts) with hepatic metastases from melanoma: a post hoc analysis of PHP-randomized versus BAC-to-PHP crossover versus BAC-only pts. J Clin Oncol 2012;30(Suppl):abstract 8570
   Google Scholar
• van Ijken MG, de Bruijn EA, de Boeck G, et al. Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs. Ann Surg 1998;228:763-70
   PubMed Web of Science ®Google Scholar